We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.95B
1-Year Est. Return 773.9%
This Fund
S&P 500
This Quarter Est. Return
+19.76%
1 Year Est. Return
+773.9%
3 Year Est. Return
+3,976.92%
5 Year Est. Return
+17,750.67%
10 Year Est. Return
+592,782.78%
AUM
$1.95B
AUM Growth
-$39.6M
Cap. Flow
-$245M
Cap. Flow %
-12.56%
Top 10 Hldgs %
59.19%
Holding
59
New
12
Increased
4
Reduced
29
Closed
9

Top Buys

Rank Stock Value
1
PBLS
Parabilis Medicines Inc
PBLS
+$128M
2
CLYM
Climb Bio
CLYM
+$21.8M
3
FTH
Faeth Therapeutics
FTH
+$16.7M
4
SYRE icon
Spyre Therapeutics
SYRE
+$16.4M
5
ANL
Adlai Nortye Group ADS
ANL
+$13.1M

Top Sells

Rank Stock Value
1
PRAX icon
Praxis Precision Medicines
PRAX
+$77.7M
2
CNTA
Centessa Pharmaceuticals
CNTA
+$41.7M
3
EWTX icon
Edgewise Therapeutics
EWTX
+$25.9M
4
OLMA icon
Olema Pharmaceuticals
OLMA
+$23.4M
5
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$23.1M

Sector Composition

Rank Sector Weight
1 Healthcare 99.09%
2 Financials 0.91%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYRE icon
26
Spyre Therapeutics
SYRE
$7.97B
$20M 1.02%
+225,000
New +$16.4M
DFTX
27
Definium Therapeutics
DFTX
$5.51B
$18.8M 0.96%
+400,000
New +$9.88M
NAMS icon
28
NewAmsterdam Pharma
NAMS
$3.1B
$16.9M 0.87%
500,000
-450,000
-47% -$14.8M
ROIV icon
29
Roivant Sciences
ROIV
$25.1B
$16.8M 0.86%
475,000
-275,000
-37% -$8.13M
CABA icon
30
Cabaletta Bio
CABA
$529M
$15.6M 0.8%
5,000,000
-500,000
-9% -$1.64M
HLXC
31
Helix Acquisition Corp III
HLXC
$238M
$13.8M 0.71%
1,297,500
– –
ASND icon
32
Ascendis Pharma A/S
ASND
$16.3B
$13.3M 0.68%
50,000
-45,000
-47% -$10.5M
KLRA
33
Kailera Therapeutics
KLRA
$2.1B
$12.1M 0.62%
+550,000
New +$12.1M
INSM icon
34
Insmed
INSM
$25.9B
$8M 0.41%
75,000
-115,000
-61% -$13.9M
FTH
35
Faeth Therapeutics
FTH
$874M
$7.66M 0.39%
1,028,242
+722,020
+236% +$16.7M
ELVN icon
36
Enliven Therapeutics
ELVN
$4.24B
$7.61M 0.39%
+150,000
New +$6.37M
TARS icon
37
Tarsus Pharmaceuticals
TARS
$3.15B
$6.29M 0.32%
100,000
-125,000
-56% -$7.99M
IBIO icon
38
iBio
IBIO
$67.6M
$6.25M 0.32%
+3,570,000
New +$6.38M
CRNX icon
39
Crinetics Pharmaceuticals
CRNX
$9B
$4.68M 0.24%
125,000
-125,000
-50% -$4.65M
ARQT icon
40
Arcutis Biotherapeutics
ARQT
$2.99B
$4.59M 0.24%
175,000
-275,000
-61% -$6.41M
ARWR icon
41
Arrowhead Research
ARWR
$12B
$4.08M 0.21%
50,000
-50,000
-50% -$3.69M
GPCR icon
42
Structure Therapeutics
GPCR
$3.38B
$4.03M 0.21%
75,000
-100,000
-57% -$4.42M
RACC
43
Research Alliance Corp III
RACC
$195M
$3.96M 0.2%
+370,000
New +$3.86M
COGT icon
44
Cogent Biosciences
COGT
$6.02B
$3.87M 0.2%
100,000
-100,000
-50% -$3.5M
ALT icon
45
Altimmune
ALT
$605M
$3.8M 0.19%
+1,250,000
New +$3.73M
AMLX icon
46
Amylyx Pharmaceuticals
AMLX
$3.87B
$3.59M 0.18%
200,000
-150,000
-43% -$2.32M
ODTX
47
Odyssey Therapeutics
ODTX
$1.17B
$3.27M 0.17%
+175,000
New +$3.07M
PCVX icon
48
Vaxcyte
PCVX
$8.9B
$2.91M 0.15%
50,000
-50,000
-50% -$2.72M
BOLD
49
Boundless Bio
BOLD
$64.4M
$2.5M 0.13%
+1,000,000
New +$1.54M
QNCX icon
50
Quince Therapeutics
QNCX
$34.3M
$100K 0.01%
+5,498
New +$126K
1
2
3

Similar funds

AHC
Adell Harriman & Carpenter Houston, Texas $1.95B AUM 52.72% 1-Year Est. Return
FFS
Founders Financial Securities Towson, Maryland $1.95B AUM 22.17% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.95B AUM 49.89% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.95B AUM 25.88% 1-Year Est. Return
BFPW
BOK Financial Private Wealth Denver, Colorado $1.95B AUM 20.52% 1-Year Est. Return
MSA
MUFG Securities Americas New York $1.95B AUM 42.71% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return
GF
Greenhouse Funds Baltimore, Maryland $1.96B AUM 36.47% 1-Year Est. Return

Cormorant Asset Management's Q2 2026 Portfolio in Review

As of Q2 2026, Cormorant Asset Management held 59 positions worth $1.95B, down 2% from $1.99B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Cormorant Asset Management withdrew a net $245M in Q2 2026, closing 9 positions and reducing 29 holdings. Its most notable exit was Centessa Pharmaceuticals, an estimated $41.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.

Against the trend, Cormorant Asset Management opened a new position in Parabilis Medicines Inc worth $126M.

  • Cormorant Asset Management's largest Q2 2026 buy was Parabilis Medicines Inc: 4,615,612 shares worth $126M.
  • Cormorant Asset Management added most to Faeth Therapeutics in Q2 2026, an estimated $16.7M increase.
  • Cormorant Asset Management's biggest Q2 2026 reduction was Praxis Precision Medicines, cutting an estimated $77.7M.
  • Cormorant Asset Management fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $41.7M.
  • Cormorant Asset Management's ten largest holdings make up 59% of its $1.95B portfolio in Q2 2026.
  • Cormorant Asset Management opened 12 new positions and closed 9 in Q2 2026.
  • Cormorant Asset Management's portfolio value fell 2% quarter-over-quarter to $1.95B.

Based on Cormorant Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.